Table 1.
Comparison between baseline characteristics of multiple myeloma patients belonging to the unmatched and propensity score (PS)-matched cohorts on first-line treatment with bortezomib-based or conventional chemotherapy alone. FABIO project, Italy, 2010–2016.
| Unmatched cohort members |
PS-matched cohort members |
|||
|---|---|---|---|---|
| Bortezomib-based therapy (n = 1325) | Conventional chemotherapy (n = 2184) | Bortezomib-based therapy (n = 1157) | Conventional chemotherapy (n = 1826) | |
| Gender | ||||
| Men | 678 (51.2) | 1079 (49.4) | 581 (50.2) | 935 (51.2) |
| Women | 647 (48.8) | 1105 (50.6) | 576 (49.8) | 891 (48.8) |
| p-value† | 0.311 | 0.599 | ||
| Age at diagnosis (years) | ||||
| <60 | 99 (7.5) | 169 (7.7) | 59 (5.1) | 103 (5.6) |
| 60–69 | 328 (24.8) | 375 (17.2) | 273 (23.6) | 489 (26.8) |
| 70–79 | 716 (54.0) | 902 (41.3) | 661 (57.1) | 998 (54.7) |
| ⩾80 | 182 (13.7) | 738 (33.8) | 164 (14.2) | 236 (12.9) |
| p-value† | <0.001 | 0.187 | ||
| Bone diseases | 236 (17.8) | 449 (20.6) | 216 (18.7) | 313 (17.1) |
| p-value† | 0.046 | 0.287 | ||
| Renal diseases | 365 (27.5) | 519 (23.8) | 283 (24.5) | 412 (22.6) |
| p-value† | 0.012 | 0.232 | ||
| Circulatory diseases | 481 (36.3) | 938 (43.0) | 418 (36.1) | 613 (33.6) |
| p-value† | <0.001 | 0.152 | ||
| Pulmonary diseases | 50 (3.8) | 195 (8.9) | 46 (4.0) | 85 (4.7) |
| p-value† | <0.001 | 0.378 | ||
| Diabetes | 239 (18.0) | 408 (18.7) | 208 (18.0) | 379 (20.8) |
| p-value† | 0.634 | 0.063 | ||
| Mental disorders | 35 (2.6) | 76 (3.5) | 30 (2.6) | 33 (1.8) |
| p-value† | 0.169 | 0.146 | ||
| Stomach | 64 (4.8) | 112 (5.1) | 208 (18.0) | 379 (20.8) |
| p-value† | 0.659 | 0.063 | ||
| Use of bisphosphonates | 119 (9.0) | 261 (12.0) | 109 (9.4) | 186 (10.2) |
| p-value† | 0.006 | 0.495 | ||
†
Chi-square test.